Learn how Cytopeutics partnered with Syngene to conduct safety and tumorigenicity studies for its hMSC product in appropriate animal models as per regulatory guidelines.

Learn how Syngene developed an antiparasitic tablet for dogs containing multiple APIs (one of which is a very low dose) in just six months.

Learn how Syngene partnered with a U.S.-based biotech company to develop and manufacture a first-in-class treatment for a rare disease affecting children.

Learn how Syngene streamlined the production process of Panbela’s pancreatic cancer drug, SBP-101, while ensuring high chiral purity of 98% during GMP manufacturing

How Syngene achieved cost minimization and quick turn-around time when scaling a client’s drug compound from lab-scale to cGMP-scale using the ‘SELECT’ criteria.

Learn how a partnership with a leading global biopharma for outsourced Bioanalytical studies for Large Molecule therapeutics evolved into a co-development partnership nearing a decade.

Learn why Baxter chose to partner with Syngene for Stability studies, the business flow, governance mechanism and metrics that were implemented, which enabled a mutully successful collaboration.

Learn how Syngene developed and commercialized for its client, a complex palatable dosage form comprising three actives for use in companion animals.

Read how Syngene’s partnership with a leading Biotech company working in the field  of cancer therapy, grew from one small pilot project to over  100 FTEs today.